BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23252945)

  • 1. Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
    Shi P; Zha J; Guo X; Chen F; Fan Z; Huang F; Meng F; Liu X; Feng R; Xu B
    Pharmacogenomics; 2013 Jan; 14(1):17-23. PubMed ID: 23252945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Improved treatment results in children with AML: Results of study AML-BFM 93].
    Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
    Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
    Wiernik PH; Case DC; Periman PO; Arlin ZA; Weitberg AB; Ritch PS; Todd MB
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):25-9. PubMed ID: 2928807
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
    Wiernik PH; Banks PL; Case DC; Arlin ZA; Periman PO; Todd MB; Ritch PS; Enck RE; Weitberg AB
    Blood; 1992 Jan; 79(2):313-9. PubMed ID: 1730080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
    Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
    Vogler WR; Velez-Garcia E; Omura G; Raney M
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
    [No Abstract]   [Full Text] [Related]  

  • 7. Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
    Wiedower E; Jamy O; Martin MG
    Anticancer Res; 2015 Nov; 35(11):6287-90. PubMed ID: 26504064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
    Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-adapted induction and consolidation therapy in adults with de novo AML aged Heil G; Krauter J; Raghavachar A; Bergmann L; Hoelzer D; Fiedler W; Lübbert M; Noens L; Schlimok G; Arnold R; Kirchner H; Ganser A
    Ann Hematol; 2004 Jun; 83(6):336-44. PubMed ID: 15034758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
    Petti MC; Mandelli F
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):10-5. PubMed ID: 2928805
    [No Abstract]   [Full Text] [Related]  

  • 13. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
    Berman E; Raymond V; Gee T; Kempin SJ; Gulati S; Andreeff M; Kolitz J; Gabrilove J; Heller G; Young CW
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):30-4. PubMed ID: 2928808
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
    Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials.
    Wang H; Xiao X; Xiao Q; Lu Y; Wu Y
    Medicine (Baltimore); 2020 Jun; 99(24):e20094. PubMed ID: 32541448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
    Giles FJ; Kantarjian HM; Cortes JE; Faderl S; Verstovsek S; Thomas D; Garcia-Manero G; Wierda W; Ferrajoli A; Kornblau S; Mattiuzzi GN; Tsimberidou AM; Albitar M; O'Brien SM; Estey E
    Leuk Res; 2005 Jun; 29(6):649-52. PubMed ID: 15863204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.
    Lee JH; Kim H; Joo YD; Lee WS; Bae SH; Zang DY; Kwon J; Kim MK; Lee J; Lee GW; Lee JH; Choi Y; Kim DY; Hur EH; Lim SN; Lee SM; Ryoo HM; Kim HJ; Hyun MS; Lee KH;
    J Clin Oncol; 2017 Aug; 35(24):2754-2763. PubMed ID: 28632487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
    Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
    Low M; Lee D; Coutsouvelis J; Patil S; Opat S; Walker P; Schwarer A; Salem H; Avery S; Spencer A; Wei A
    Intern Med J; 2013 Mar; 43(3):294-7. PubMed ID: 22757980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
    Ruutu T; Almqvist A; Hallman H; Honkanen T; Järvenpää E; Järventie G; Koistinen P; Koivunen E; Lahtinen R; Lehtinen M
    Leukemia; 1994 Jan; 8(1):11-5. PubMed ID: 8289475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.